Extended release
VDPHL01 is being investigated as an extended-release oral minoxidil formulation.
CLINICAL RESEARCH EXPLORER
The evidence.
In context.
The research programme involves separate investigational studies in male and female pattern hair loss. Explore the designs, outcomes and important limitations.
MALE STUDY 302 · PHASE 2/3
30.3
Hairs/cm² mean increase at Month 6
Once-daily arm versus 7.3 hairs/cm² in placebo. Reported trial: 519 male participants; randomised, double-blind, placebo-controlled.
EARLIEST ASSESSMENT
Month 2
Statistically significant increase was reported at the earliest prespecified assessment in the male study.
These developer-reported topline data are not approved treatment claims.
FEMALE STUDY 207 · OPEN-LABEL
22.7
Hairs/cm² mean increase at Month 6
Once-daily female arm in an open-label Phase 2 study without a placebo comparator.
PARTICIPANT-REPORTED COVERAGE
88.9%
Reported improved or much-improved hair coverage in the specified once-daily female arm at Month 6.
Open-label findings may be influenced by lack of blinding and absence of a placebo comparison.
VDPHL01 remains investigational. These are developer-reported findings from separate trials, not a direct comparison or guarantee of individual benefit.
FORMULATION DEVELOPMENT
Designed for clinical investigation.
Study outcomes
Clinical trials assess target-area hair-count changes as well as safety and tolerability.
Regulatory evaluation
Future benefits, risks and permitted uses depend on completed studies and authorisation.
RESEARCH SOURCES
Transparency matters.
Clinical data originate from Veradermics' VDPHL01 development programme. The original announcements remain the primary source of the statistics on this website.
WHAT COMES NEXT
Curiosity meets possibility.
Follow the research, the evolving brand and future availability updates where permitted.
Register interest